Galapagos CEO Onno van de Stolpe said the company has identified five candidate drugs of which two have been in-licensed by GSK to date, since the start of the alliance in 2006.
"We hope that more programs from this alliance may enter the clinic," Onno van de Stolpe added.
In 2006 the companies entered into an agreement to discover and develop disease-modifying drugs for GSK’s global R&D organization.
Under the agreement, Galapagos is eligible to earn more than €200m in total milestone payments in addition to royalties from GSK.